Clinical Trial Update: IRAK 4 Inhibitor (PF-06650833) in Hospitalized Patients With COVID-19 Pneumonia and Exuberant Inflammation. [Phase 2]

View source ↗

Summary

Phase 2 clinical trial investigating an IRAK 4 inhibitor (PF-06650833) for hospitalized COVID-19 pneumonia with exuberant inflammation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• COVID-19 Pneumonia

Drugs mentioned

• PF-06650833 (PF-06650833)

Snippet

Sponsor: Giovanni Franchin, M.D, Ph.D | Conditions: COVID-19 Pneumonia | Phase 2 | Status: UNKNOWN